Gala GLP-1 Review: The $179 Is a Year Up Front and the Year Is 48 Weeks

And then the arithmetic

The standing month-to-month price is $299, rising to $399 on the higher tier. That is the first thing the "$179/mo" headline does not say, though the footnote at least points at it.

The second is not disclosed anywhere, and it is the one that costs real money.

Gala bills on a four-week cycle. A calendar year contains 52 weeks, which is 13 four-week cycles, not 12. At the standing $299 that is roughly $3,887 a year, against the $3,588 that "per month" implies — about $300 the monthly figure never mentions.

The same arithmetic runs the other way on the annual plan, and this is the sharper version. Gala's "12-month" plan ships twelve four-week cycles. Twelve times four weeks is 48 weeks. A year is 52.

So a patient who prepays for what is described as twelve months receives eleven months and a week of medication. The plan is not mislabelled by a rounding error; it is short by a month, and nothing on the page says so.

Paid before you are assessed

Gala charges the card at the completion of the intake — before a clinician has reviewed the case. Refunds are unavailable except where a patient is medically disqualified.

Put those two together and the shape is: you pay, then you are assessed. If the assessment goes against you, you are refunded. If it goes in your favour and you have changed your mind in the meantime, the money is gone.

That is a materially different bargain from the one several competitors offer, and it is worth understanding before starting an intake rather than after.

The longevity product with no trial

Alongside its main line, Gala sells "Microdosing — GLP-1/GIP incl. tirzepatide" at $149 a month, described elsewhere on the site as a "low-dose longevity protocol".

Tirzepatide has a large, genuine phase 3 programme. SURMOUNT-1 enrolled 2,539 participants and ran 72 weeks. ¹ What it tested was a titrated therapeutic dose, measured against weight and cardiometabolic endpoints.

It did not test a sub-therapeutic dose. It did not measure ageing, healthspan or longevity in any form. No registered trial has.

Selling a deliberately reduced dose as a longevity intervention asserts a dose-response relationship for an outcome nobody has measured — and Gala's otherwise careful disclaimer, that results are "based on clinical studies of GLP-1 medications", is carried onto this product too, where there are no clinical studies to base anything on.

Who compounds it

Nobody named. Gala's disclosure that the product is "sourced from licensed compounding pharmacies" is honest as far as it goes, and it goes no further: no pharmacy name, no address, no phone number, no state map.

The consequence is practical. Gala publishes no certificate of analysis, no lot number, no potency or sterility result — which is true of every company in this wave — but here there is also no party to ask. Other companies withhold the document and name the pharmacy; a patient can at least ring it. Here there is nobody on the other end of the question.

The clinical side is disclosed properly: "Medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated medical practices, including OpenLoop-affiliated medical groups… Gala provides administrative, technology, and management services and does not provide medical care." The corporate entity is AI Coaching, Inc.

*(One identity note, because the name invites a mistake: galahealth.com is a parked domain and is not this company. The match here is on galaglp1.com and on AI Coaching, Inc.)*

The brand-name listing

Gala lists Ozempic® at $1,299 a month, correctly identified as brand-name semaglutide rather than blurred into the compounded line.

Two things about that price. It is several times what Novo Nordisk charges self-paying patients directly through its own pharmacy channel, and any telehealth prescriber can route a prescription there instead. And Ozempic's own approval is for type 2 diabetes — Wegovy is the weight-management approval of the same molecule — so listing it under "GLP-1 for Weight Loss" describes an off-label use. That is lawful and common, and Gala does not claim otherwise; it simply is not the approved indication.

Pressure in the funnel

Gala's intake carries devices that do not survive being watched: a stock counter that decrements as you interact with the page rather than as inventory moves, and patient-count figures that differ from one screen to the next.

None of that affects the medicine. It affects how much weight to put on anything else the funnel tells you, which is why it is recorded here.

(One caution for anyone re-checking this site: a static fetch of the home page renders a headline percentage as "0%", because the figure is an animated counter that has not run. That is a capture artefact, not a claim by Gala, and it should not be quoted as one.)

What this means if you are buying

Gala is a reasonable place to buy a compounded GLP-1, and it is more candid than most about what a compounded GLP-1 is. Read the price the way its own footnote tells you to.

Budget $299, not $179, unless you are prepaying a year. If you are prepaying a year, know that the year is 48 weeks. And if you are paying month to month, expect thirteen charges over a calendar year rather than twelve, because the cycle is four weeks.

Do not start the intake until you are ready to pay, because the charge lands before the clinical review, and it will not come back unless you are medically disqualified.

The microdosing product is sold as longevity, and there is no trial of a low-dose GLP-1 against any ageing endpoint.

And if you are here looking for peptides more broadly, Gala sells none — no sermorelin, no NAD+, nothing beyond the GLP-1s themselves.